CTIS2023-508398-10-00进行中（未招募）1 期
Discontinuation of rituximab compared with rituximab maintenance in ANCA-associated vasculitis – a randomized non-blinded controlled trial (DISRITUX)
Region Oestergoetland0 个研究点目标入组 96 人开始时间: 2024年3月7日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Informed consent given by patient according to national regulations, AAV [granulomatosis with polyangiitis or microscopic polyangiitis], according to the definitions of the Chapel Hill Consensus Conference, Current or history of PR3/MPO-ANCA positivity by ELISA, A stable remission (BVAS =0) for the last 24 months, Has received a minimum of 24 months of RTX maintenance therapy and last dose minimum 6 months prior to screening. A Rituximab dose of 500 mg or 1000 mg 6 months before inclusion will be accepted, Females of childbearing potential must agree to avoid pregnancy during treatment with RTX during 12 months after discontinuation of RTX. They also must have a negative urine or serum pregnancy test at the screening visit. Adequate contraception methods must be followed according to clinical routine for these patients
排除标准
- •Significantly abnormal eGFR at screening (=15 eGFR ml/min/1.73m2), Hypogammaglobulinemia, IgG <3 g/L, History of malignancy within the past five years or any evidence of persistent malignancy. Fully excised basal cell or squamous cell carcinomas of the skin, or cervical carcinoma in situ which has been treated or excised in a curative procedure is allowed, Females who are lactating or pregnant at screening (verified with a negative urine or serum pregnancy test at screening visit)., Medical, psychiatric, cognitive, or other conditions that, in the investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study, Participant in another clinical trial with therapeutic intervention or use of any other investigational agent, Previous therapy with any of the following: - any biological B cell depleting agent other than rituximab during the last 6 months (i.e Obinutuzumab, Belimumab) - IVIg, infliximab, etanercept, adalimumab, abatacept or plasma exchange in past 3 months - any investigational agent within 28 days of screening, or 5 half-lives of the investigational drug (whichever is longer), Ongoing therapy with any of the following. - disease modifying therapy related for AAV such as methotrexate, azathioprine, and mycophenolate mofetil or glucocorticoid >5 mg daily, Recurrent AAV relapses less than 6 months off immunosuppressive medication, Significant or uncontrolled medical disease not related to AAV, which in the investigator’s opinion would preclude patient participation, Presence of another multisystem autoimmune disease, including Churg Strauss syndrome, systemic lupus erythematosus, anti-GBM disease, or cryoglobulinaemic vasculitis, History of severe allergic or anaphylactic reactions to humanized or murine chimeric monoclonal antibodies, Past or current history of hepatitis B virus, current active hepatitis C, Bone marrow suppression as evidenced by a total white count < 3.0 x109/l and/or neutropenia neutrophil count < 1.5 × 109
研究者
相似试验
进行中（未招募）
1 期
Comparison of two treatments rituximab in patients with autoimmune disease resistant to conventional treatmentsEUCTR2011-005856-32-ESFundación Progreso y Salud9
招募中
3 期
Efficacy of rituximab in comparison to continued corticosteroid treatment in idiopathic nephrotic syndrome unresponsive to 8 weeks of high dose prednisone.focal segmental glomerulosclerosisidiopathic nephrotic syndromeminimal change disease10029149NL-OMON44222Radboud Universitair Medisch Centrum40
进行中（未招募）
1 期
Comparison of rituximab with prolonged treatment with prednisone in patients with idiopathic nephrotic syndromeEUCTR2017-003366-27-NLRadboud University Nijmegen Medical Center40
进行中（未招募）
1 期
Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study. - REOVASEUCTR2016-000275-25-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)108
尚未招募
不适用
Comparison between single dose and multiple dose Rituximab in idiopathic membranous nephropathyCTRI/2020/11/029094RS Medical College and Hospital